Announcements Trials
Browse Landscape

Phase

Phase 1/2 1Phase 1 1

Status

Completed 8Recruiting 2Unknown 1Terminated 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gynecologic 2Gastrointestinal 2CNS 2Thoracic 1Head & Neck 1Genitourinary 1Dermatologic 1

Conditions

Carcinoma, Non-Small-Cell Lung 47Breast Neoplasms 39Ovarian Neoplasms 35Triple Negative Breast Neoplasms 24Endometrial Neoplasms 20Stomach Neoplasms 19Squamous Cell Carcinoma of Head and Neck 17Fallopian Tube Neoplasms 17Lung Neoplasms 16Esophageal Squamous Cell Carcinoma 14Parkinson Disease 4, Autosomal Dominant Lewy Body 13Neoplasm Metastasis 13Esophageal Neoplasms 13Neoplasms 12Uterine Cervical Neoplasms 11Carcinoma, Ovarian Epithelial 10Head and Neck Neoplasms 7Recurrence 6Carcinoma 6Colorectal Neoplasms 5Adenocarcinoma 5Uterine Neoplasms 4Small Cell Lung Carcinoma 4Oropharyngeal Neoplasms 4Melanoma 4Carcinoma, Transitional Cell 4Advanced Solid Tumors 4Adenocarcinoma Of Esophagus 4Carcinoma, Squamous Cell 3Carcinoma, Renal Cell 3

Interventions

Radiotherapy 3Nivolumab 3pembrolizumab 2Temozolomide 2Surveys and Questionnaires 2Paclitaxel 2ONC206 2Magnetic Resonance Spectroscopy 2Magnetic Resonance Imaging 2Etoposide 2Cyclophosphamide 2Carboplatin 2Biopsy 2regorafenib 1pegfilgrastim 1mirdametinib 1lutetium Lu 177 dotatate 1fludarabine 1etoposide phosphate 1entrectinib 1entinostat 1elacestrant 1decitabine and cedazuridine drug combination 1cabozantinib 1amino-acid, glucose, and electrolyte solution 1alectinib 1aflibercept 1abemaciclib 1Topotecan 1Tissue Banks 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Recruiting × Central Nervous System Neoplasms × Paclitaxel × Clear all
NCT06840886 2026-05-14

A Study of PHST001 in Advanced Solid Tumors

Pheast Therapeutics

Phase 1 Recruiting
272 enrolled
CNSGastrointestinalGynecologic

Ovarian Neoplasms, Central Nervous System Neoplasms, Endometrial Neoplasms, Cholangiocarcinoma

NCT06047379 2026-03-02

Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis

Neonc Technologies, Inc.

Phase 1/2 Recruiting
134 enrolled
CNSDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Esophageal Squamous Cell Carcinoma, Astrocytoma, Brain Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Squamous Cell, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Esophageal Neoplasms, Glioblastoma, Melanoma, Stomach Neoplasms, Colorectal Neoplasms, Carcinoma, Merkel Cell, Central Nervous System Neoplasms, Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡